Learn More
BACKGROUND Owing to the limited validity of clinical data on the treatment of prostate cancer (PCa) and bone metastases, biochemical markers are a promising tool for predicting survival, disease progression and skeletal-related events (SREs) in these patients. The aim of this study was to evaluate the predictive capacity of biochemical markers of bone(More)
The purpose of this study was to evaluate the efficacy, assessed as response rate, and toxicity of UFT (Tegafur-Uracil) in combination with oxaliplatin as first-line treatment of advanced colorectal cancer (CRC). In all, 84 patients with recurrent or metastatic CRC with measurable disease were included. Treatment consisted of oxaliplatin 85 mg m(-2) in(More)
3726 Background: To assess the efficacy and safety of the oxaliplatin-UFT-l,LV combination as first-line treatment in patients with advanced CRC. METHODS Between 04/99 and 01/00, 81 patients with recurrent or metastatic CRC were included. Mean age was 63 years (40-77), male/female ratio 46/35, ECOG 0/1/2 39/36/6. The study regimen consisted of Oxaliplatin(More)
  • 1